New Review on PROSTVAC(TM) published by key Investigators from NCI
A just published Review in the publication "Expert Opinion on
Investigational Drugs", Volume 18, Issue 7 2009, confirms the
previous published information on PROSTVAC(TM). This is the most
comprehensive and updated Review on PROSTVAC(TM) so far.
Quote from the article: "Preliminary clinical trials have indicated
negligible toxicity, and Phase II trials have suggested a survival
benefit after treatment with PROSTVAC(TM), especially in patients
with indolent disease characteristics."
Anders Hedegaard, President & CEO of Bavarian Nordic said: "We are
very pleased that the scientific experts once again confirm their
positive view on PROSTVAC(TM) and the potential use of the vaccine in
earlier stages of the disease. We are looking forward to publish more
data at a later stage."
Background information:
PROSTVAC(TM) is a therapeutic vaccine moving into late stage clinical
development that has the potential to extend the lives of people with
advanced prostate cancer. Administered subcutaneously, it induces a
specific, targeted immune response that attacks prostate cancer
cells. Conventional chemotherapy currently used to treat prostate
cancer has limited survival rates and is often associated with
numerous side effects. In contrast, PROSTVAC(TM) has the potential to
extend survival with improved quality of life. PROSTVAC is being
developed in collaboration with the National Cancer Institute under a
Cooperative Research and Development Agreement with Bavarian Nordic's
U.S.-based subsidiary, BN ImmunoTherapeutics.
In clinical trials to date PROSTVAC(TM) and related PSA containing
poxviral vaccines have been investigated in more than 500 patients
for 10 years.
Asger Aamund
Chairman
